Journal: Scientific Reports

Article Title: Characterization of a pleomorphic rhabdomyosarcoma cell line

doi: 10.1038/s41598-025-87027-2

Figure Lengend Snippet: IC 50 -values of BAY-293, ARV-771, MZ1, Cisplatin, Cyclophosphamide, Epirubicin, Topotecan, BI-5521 and WEE1 on cell lines RD, TE671 and BH1522. Data represent mean values ± SD. There were significant differences between TE671 and BH1522 regarding Cisplatin and Topotecan. Further, there were significant differences between BH1522 and TE671 as well as BH1522 and RD regarding ARV-771.

Article Snippet: Cyclophosphamide (Catalog No. S1217), Topotecan (Catalog No. S9321) and WEE1 (Catalog No. S1525) were purchased from Selleckchem (Houston TX, USA).

Techniques:

Journal: Molecular Cancer Therapeutics

Article Title: Novel missense mutation of the DNA topoisomerase I gene in SN-38-resistant DLD-1 cells

doi: 10.1158/1535-7163.mct-05-0246

Figure Lengend Snippet: Figure 1. Cytotoxicity of camptothecin derivatives. Parental DLD-1 cells and resistant DLDSNR6 cells were cultured for 72 h in the presence of the indicated SN-38, camptothecin, and topotecan concentrations. Cell viability was determined by the 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethony- phenol)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt assay. Bars, SD for three independent experiments.

Article Snippet: Drugs and Antibodies SN-38 was kindly provided by Yakult Co. Ltd. (Tokyo, Japan), topotecan was purchased from LKT Laboratories (St. Paul, MN), and other drugs were purchased from Sigma (St. Louis, MO).

Techniques: Cell Culture

Journal: bioRxiv

Article Title: Frontotemporal dementia patient-derived iPSC neurons show cell pathological hallmarks and evidence for synaptic dysfunction and DNA damage

doi: 10.1101/2024.04.12.589061

Figure Lengend Snippet: NUPR2, potentially related to the DNA damage pathway, is the only differentially expressed gene when comparing the C9-HRE and sporadic FTD neurons ( A ). Both sporadic and C9-HRE-carrying FTD neurons display nuclei, which are significantly rounder in shape as well as significantly smaller compared to healthy neuron nuclei, indicated by altered nuclear eccentricity ( B ), and a higher number of micronuclei ( C ). A representative image of a micronucleus next to the nucleus is shown (arrow). Kruskal-Wallis test followed by Dunn’s multiple comparisons test was used. n [Control] = 74; n [C9-] = 17; n [C9+] = 21. In addition, the distribution of larger and smaller sized nuclei is different in FTD neurons than that in control neurons ( D-F ). Topotecan treatment significantly increases the number of γH2A.X-positive foci in the nuclei in all neurons, indicating increased DNA damage. At baseline, C9+ neurons display a slightly higher number of γH2A.X foci compared to HC neurons, although this difference is not statistically significant ( H-J ). Kruskal-Wallis test followed by Dunn’s multiple comparisons test was used. n [Control] = 26-28; n [C9-] = 15-18; n [C9+] = 44-64. Statistically significant differences are shown as *p < 0.05, **p <0.01, and ***p <0.001.

Article Snippet: To study the DNA damage response, iPSC-derived neurons were treated with 10 μl topotecan (Topotecan hydrochloride, Tocris, 4562) or DMSO vehicle for 1h.

Techniques: Control

Journal: Drug Delivery

Article Title: Inhalation delivery dramatically improves the efficacy of topotecan for the treatment of local and distant lung cancer

doi: 10.1080/10717544.2021.1912209

Figure Lengend Snippet: Efficacy of inhaled vs. IV topotecan against orthotopic lung tumors in rats. (A) Gross and histological pictures of lungs from an age-matched normal (left) and H358-derived lung tumors from an untreated control (right) animals. (B) The tumor burden in the three treatment groups.

Article Snippet: The spray-dried powder formulation of topotecan was manufactured from (S)-topotecan (Toronto Research Chemicals, Inc., Toronto, Canada) and its physical, chemical, and aerosol characteristics were determined as described (Kuehl et al., ).

Techniques: Derivative Assay

Journal: Drug Delivery

Article Title: Inhalation delivery dramatically improves the efficacy of topotecan for the treatment of local and distant lung cancer

doi: 10.1080/10717544.2021.1912209

Figure Lengend Snippet: Inhalation delivery of topotecan is more effective in treating H358-derived orthotopic lung tumors compared to two times higher IV dose.

Article Snippet: The spray-dried powder formulation of topotecan was manufactured from (S)-topotecan (Toronto Research Chemicals, Inc., Toronto, Canada) and its physical, chemical, and aerosol characteristics were determined as described (Kuehl et al., ).

Techniques:

Journal: Drug Delivery

Article Title: Inhalation delivery dramatically improves the efficacy of topotecan for the treatment of local and distant lung cancer

doi: 10.1080/10717544.2021.1912209

Figure Lengend Snippet: Pharmacokinetic analysis of topotecan following IV or inhalation delivery in mice. The mean levels of topotecan (ng/mL) detected in the (A) plasma, (B) lung, (C) liver, and (D) brain tissues of mice at various time points following 5 mg/kg IV or 1 mg/kg inhalation delivery of the drug.

Article Snippet: The spray-dried powder formulation of topotecan was manufactured from (S)-topotecan (Toronto Research Chemicals, Inc., Toronto, Canada) and its physical, chemical, and aerosol characteristics were determined as described (Kuehl et al., ).

Techniques:

Journal: Drug Delivery

Article Title: Inhalation delivery dramatically improves the efficacy of topotecan for the treatment of local and distant lung cancer

doi: 10.1080/10717544.2021.1912209

Figure Lengend Snippet: Pharmacokinetics profile of topotecan following inhalation or IV delivery.

Article Snippet: The spray-dried powder formulation of topotecan was manufactured from (S)-topotecan (Toronto Research Chemicals, Inc., Toronto, Canada) and its physical, chemical, and aerosol characteristics were determined as described (Kuehl et al., ).

Techniques:

Journal: Drug Delivery

Article Title: Inhalation delivery dramatically improves the efficacy of topotecan for the treatment of local and distant lung cancer

doi: 10.1080/10717544.2021.1912209

Figure Lengend Snippet: Inhalation delivery of topotecan leads to superior efficacy against lung tumors at distant sites than IV delivery. The growth of tumors derived from (A) the KRAS mutant A549, (B) the KRAS and EGFR wildtype H358, and (C) the EGFR mutant H1975 human NSCLC cell lines revealed a superior efficacy of 1 mg/kg inhaled topotecan compared to 5 mg/kg IV topotecan. (D, E) The average weights of these tumors obtained at the end of the study further confirmed the tumor measurement data. Significant differences ( p <.05) from vehicle control and IV topotecan treated groups are shown as * and ϕ, respectively.

Article Snippet: The spray-dried powder formulation of topotecan was manufactured from (S)-topotecan (Toronto Research Chemicals, Inc., Toronto, Canada) and its physical, chemical, and aerosol characteristics were determined as described (Kuehl et al., ).

Techniques: Derivative Assay, Mutagenesis